Thermo Fisher Scientific has announced that Dr Eric Gluck will host a scientific presentation highlighting the benefits of the Thermo Scientific B.R.A.H.M.S procalcitonin (PCT) assay at SCCM 2011.
The Society of Critical Care Medicine (SCCM) Critical Care Conference will be the 40th to take place.
Dr Eric Gluck is an early adopter of procalcitonin and will provide insight into the benefits of using the protein as a biomarker for sepsis and its utility in the intensive care unit at Swedish Covenant Hospital to assist in identifying sepsis in critically ill patients.
PCT is a protein biomarker that can be detected in human serum and plasma.
The Thermo Scientific B.R.A.H.M.S PCT biomarker assay enables rapid and accurate risk assessment for progression to severe sepsis and septic shock, which is of particular benefit to intensive care units in hospitals.
Sepsis is characterised by a whole-body inflammatory state due to systematic infection, which can result in organ failure and death.
PCT is a protein that can be used as a marker for sepsis allowing for identification and risk assessment.
Unlike other sepsis biomarkers, the B.R.A.H.M.S PCT biomarker assay has been shown to accurately predict the absence of the condition early in the diagnosis stage, reducing costs and unnecessary antibiotic use.
Test implementation is efficient and practical, blood samples can be prepared and analysed in 19 minutes and patient results delivered one hour from taking the blood sample.
In addition, levels of PCT in the human body correlate to the severity of the infection, enabling a more accurate and detailed assessment.
Dr Eric Gluck will present a seminar expanding on this information at the Thermo Scientific booth 432 on Monday 17 January at 10am, 12 noon and 2pm Pacific Time.
Further to the presentation, Thermo Fisher Scientific will showcase the B.R.A.H.M.S PCT biomarker assay at the Thermo Scientific booth 432 during SCCM 2011, 15-19 January in San Diego.
